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Abstract
Background: Malaria is an annual killer of over one million people globally and its essential co-morbidity
is anaemia. Cord blood, because of its rich mix of foetal and adult haemoglobin, high platelet and WBC
counts, hypo-antigenic nature, altered metabolic profile and high affinity for oxygen as well as its anti-
malarial effect, is an ideal choice in malaria with anaemia, necessitating blood transfusion.
Methods: This paper presents an alternative protocol for fresh whole blood/packed cell transfusion from
the hospital's biological waste resources, i.e., the placenta, after the birth of a healthy baby from a healthy
mother. This collected blood was routinely transfused to patients admitted in our hospital with severe
anaemia in the background of confirmed malaria. 94 units of placental umbilical cord whole blood were
collected after lower uterine caesarean section (LUCS) from consenting mothers (from 1st April 1999 to
April 2005), and safely transfused to 39 informed, consenting patients (age varying from 8 to 72 years).
The collected volume of cord blood from each placenta (Unit) varied from 52 ml to 143 ml, with a mean
packed cell volume of 48.9 ± 4.1 SD and a mean haemoglobin concentration of 16.4 Gm percent ± 1.6 Gm
percent SD. The blood was immediately transfused after following the standard adult blood transfusion
protocol of screening and cross-matching between the donor and the recipient. On occasion, the collected
cord blood was preserved in the refrigerator, if no volunteer was readily available, and transfused within
72 hours of collection.
Results: Cord blood transfusion was tested on twenty two patients infected with Plasmodium falciparum
and 17 patients with Plasmodium vivax. For inclusion in this study, the patient's plasma haemoglobin had to
be 8 gm percent or less (the pre-transfusion haemoglobin in the malaria-infected patients in this series
varied from 5.4 gm/dl to 7.9 gm/dl). The rise of haemoglobin within 72 hours of two units of freshly
collected cord blood transfusion was 0.5 gm/dl to 1.6 gm/dl. Each patient received two to six units of
freshly collected cord blood transfusion (two units at a time), depending on availability and compatibility.
No clinical immunological or non-immunological reaction has been encountered in this series.
Conclusion: Properly screened cord blood is safe for transfusion, in victims of severe malarial anaemia
who need transfusion support.
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Background
Malaria, caused by infection with Plasmodium falciparum,
kills over 1 million people each year [1]. Anaemia due to
malaria is a major health problem in endemic areas, par-
ticularly for young children and pregnant women. This
anaemia is caused by excess removal of non-parasitized
erythrocytes in addition to immune destruction of parasi-
tized red cells and impaired compensation for this loss by
bone marrow dysfunction. Though P. falciparum is the
predominant cause of anaemia and its complications,
Plasmodium vivax can also cause anaemia and thrombocy-
topaenia requiring hospitalization, although to a much
lesser extent.
To combat severe anaemia, several options are available:
concentrated fresh red blood cell (RBC) transfusion,
erythropoietin injection, blood substitutes (oxygen carri-
ers like perflurocarbon compounds, etc), dietary supple-
mentation of haematinics along with other essential
nutrient support needed for proper erythropoiesis.
The problem, however, lies in the availability of properly
screened blood, in many areas of the developing world.
The cost and complications of erythropoietin therapy,
which has fuelled the continued search for an ideal blood
substitute, is an added difficulty. In a report of the World
Health Organization, it was observed that there are about
500,000 pregnancy-related deaths globally, of which at
least 25 percent maternal deaths are due to the loss of
blood [2]. An estimated 13 million units of blood world-
wide are not tested against human immunodeficiency
viruses or hepatitis viruses, and in some developing coun-
tries 80 percent of the blood supply comes from paid
donors or replacement donors (family friends or
acquaintances) even when the virus-infected population
is high [3].
Concerns about the safety and adequacy of the blood sup-
ply have fostered twenty years of global research into the
so-called "blood substitutes" among them the oxygen car-
riers based on modified haemoglobin.
Foetal haemoglobin is a natural stress response to haemo-
globin synthesis, which may be augmented in case of tha-
lassemia by hydoxyurea treatment. Other conditions like
pregnancy, diabetes, thyroid disease or anti-epileptic drug
therapy, can also increase the foetal haemoglobin concen-
tration. Placenta is an abundant source of foetal haemo-
globin and placentas are an unused resource: in India
Graphical impact of 2 units of cord blood transfusion on the  host's creatinine level as seen after 72 hours Figure 3
Graphical impact of 2 units of cord blood transfusion 
on the host's creatinine level as seen after 72 hours. 
Series 1: pre-transfusion Creatinine in mg/dl. Series 2: post-
transfusion Creatinine in mg/dl after 72 hours.
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Graphical impact of 2 units of cord blood transfusion on the  host after 72 hours Figure 1
Graphical impact of 2 units of cord blood transfusion 
on the host after 72 hours. Series 1: pre-transfusion hae-
moglobin in Gm/dl. Series 2: post-transfusion haemoglobin in 
Gm/dl (after 72 hours).
0
1
2
3
4
5
6
7
8
9
10
13579 1 1 1 3 1 5 1 7 1 9
Randomly selected number of cases
H
a
e
m
o
g
l
o
b
i
n
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
i
n
 
G
m
/
d
l
Série1
Série2
Graphical impact of 2 units of cord blood transfusion on the  host after 72 hours and 7 days Figure 2
Graphical impact of 2 units of cord blood transfusion 
on the host after 72 hours and 7 days. Series 1: pre-
transfusion haemoglobin in Gm/dl. Series 2: post-transfusion 
haemoglobin in Gm/dl after 72 hours. Series 3: post-transfu-
sion haemoglobin in Gm/dl after 7 days.
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alone, there are more than 20 million placentas produced
every year of which 99.9% are discarded.
Materials and methods
Whether foetal haemoglobin-rich placental umbilical
cord whole blood (which has the potential to carry more
oxygen to the tissue Vol/Vol than adult blood, because of
its foetal haemoglobin component) can be a safe substi-
tute for adult blood, if collected aseptically after the birth
of a healthy newborn at or near term, is the main scientific
query behind the present study. Human placental umbil-
ical cord blood was collected from consenting mothers
aseptically after lower uterine Caesarean section under
general or regional anesthaesia. If there was gross prema-
turity or dysmaturity or the projected weight of the foetus
was less than 2 kg, or if the mother was suffering from any
specific disease like hepatitis or HIV, etc., the cord blood
collection was abandoned. The collection process started
only after the baby was safely removed from the operation
field. Another sample of the cord blood collected from the
placenta was immediately tested for blood group (Rh and
ABO), Human Immunodeficiency Virus (HIV 1 and 2),
hepatitis B and C, VDRL, malaria, bacterial and fungal
infections. When the collection was complete, the blood
bag tubing was closed, sealed, and transfused to a malaria
victim as early as possible as per standard blood transfu-
sion protocol, as previously reported [4-6]. Host bilirubin,
urea, creatinine, glucose, were also tested along with Hb/
TC/DC/ESR, before transfusion and the tests were
repeated 72 hours after transfusion in some randomly
selected cases to see the effect of transfusion on the rise of
haemoglobin, as well as the impact on the host's hepato-
renal and metabolic profile, using standard methods.
If a patient with confirmed malaria, whose haemoglobin
was less than 8 gm/dl, was not readily available, the cord
blood was stored between 1°C and 4°C. This blood was
transfused within three days of collection to a malaria
patient with anaemia as per specifications mentioned ear-
lier, following the World Health Organization (WHO)
standard adult blood transfusion guidelines and strictly
adhering to the institutional ethical committee rules and
the patient consent protocol.
Results and discussion
39 patients with confirmed malaria were randomly
selected for the present study after approval was given by
the Institutional ethical committee for each case and the
voluntary patient consent protocol was followed. The age
of the patients varied from 8 to 72 years, (mean 39.4
years), of whom 24 were male and 15 were female. In this
series, twenty-two patients were infected with P. falci-
parum and seventeen had P. vivax infection.
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Graphical impact of 2 units of cord blood transfusion on the 
host's bilirubin level as seen after 72 hours.
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Graphical impact of 2 units of cord blood transfusion on the  host's urea level as seen after 72 hours Figure 4
Graphical impact of 2 units of cord blood transfusion 
on the host's urea level as seen after 72 hours. Series 
1: pre-transfusion Urea level in mg/dl. Series 2: post-transfu-
sion Urea level in mg/dl after 72 hours.
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Graphical impact of 2 units of cord blood transfusion on the  host's glucose level as seen after 72 hours Figure 5
Graphical impact of 2 units of cord blood transfusion 
on the host's glucose level as seen after 72 hours. 
Series 1: pre-transfusion glucose in mg/dl. Series 2: post-
transfusion glucose in mg/dl (after 72 hours).
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The 94 units of cord blood (52 ml to 143 ml in volume,
mean 81 m1+6.6 ml SD, median 82 ml, mean packed cell
volume 48.9 + 4.1 SD, mean haemoglobin concentration
16.4 Gm percent + 1.6 Gm percent SD) were transfused to
the 39 informed, consenting patients from 1 April 1999 to
April 2005. Two units were transfused at a time to individ-
ual patients. The recipient who got the maximum amount
received six units of placental blood.
The pathophysiology [7], iron metabolism [8,9] and
erythropoietin production [10] in case of anemia in
chronic disease is different. The amount of transfusion
depended on the severity of anaemia and the availability
of compatible and screened cord blood. The pre-transfu-
sion haemoglobin in the malaria infected patients in this
study varied from 5.4 gm/dl to 7.9 gm/dl for falciparum
infection and 6.3 gm/dl – 7.8 gm/dl in vivax-infected
patients. The rise of haemoglobin as estimated after 72
hours of the transfusion of two units of cord blood was
0.5 gm/dl to 1.6 gm/dl (Figure 1). What is interesting is
the fact that there is a slow but sustained rise of haemo-
globin on the seventh day after transfusion (series 3).
A univariate analysis using Fishers' exact test was per-
formed for the results of series 2 (rise of haemoglobin
after 72 hours from pre-transfusion value) and series 3
(rise of haemoglobin after 7 days from pre-transfusion
value). The difference between Group 2 and 3 values and
its comparison with the pre-transfusion haemoglobin
appeared to be statistically significant (p < less than .003).
This effect could be due to the bone marrow stimulating
effect of the different cytokine systems of the placental
blood (Figure 2). No immunological or non-immunolog-
ical reaction or adverse metabolic impact on the recipient
has been encountered so far. There was no detected rise of
serum creatinine (Figure 3), urea (Figure 4), glucose (Fig-
ure 5), bilirubin (Figure 6), on the recipients of two units
of cord blood, when compared to the pre-transfusion
level. There was also an improvement of appetite and a
sense of well being in all the recipients of cord blood
transfusion.
Conclusion
The placenta is a rich source of cord blood (at term there
is up to 150 ml of blood in placental circulation). Cord
blood is protected from infection as a result of nature's
finest biological sieve [11,12], i.e., the placenta and con-
tains 60–80% foetal haemoglobin (which can carry 60%
more haemoglobin than adult haemoglobin) and has also
a high WBC and platelet content, is hypo-antigenic in
nature, and has an altered metabolic profile. It may also
have the potential, due to its rich cytokine and growth fac-
tor content [13], to play a role in immune response mod-
ification in chronic anaemia.
In the developed world, umbilical cord blood (UCB) is
now accepted as an alternative source for haematopoietic
stem cells for transplantation, especially in children, in
view of its many practical advantages. Currently there are
about 100,000 units available worldwide [14]. The high
oxygen affinity and anti-malarial effect of foetal haemo-
globin in cord blood are additional advantages for trans-
fusion in malaria patients with anaemia [15].
Acknowledgements
The author acknowledges with gratitude the patients who volunteered for 
the work. The Dept of Science and Technology, Govt of West Bengal, sup-
ported the work with a grant to the investigator (Dr Niranjan Bhattachaya) 
from 1999–2002. Without its support, the work presented in this paper 
could not have been done.
References
1. World Health Organization: Severe falciparum malaria.  Trans R
Soc Trop Med Hyg 2000, 94(Suppl 1):S1-90.
2. World Health Organization, International Federation of Red Cross
and Red Crescent Societies: 'Safe blood starts with me'.  Geneva,
World Health Organization; 2000:12. 
3. Sloand EM, Pitt E, Klein HG: Safety of blood supply.  JAMA 1995,
274:1368-1373.
4. Bhattacharya N, Mukherjee KL, Chettri MK, et al.: A study report
of 174 units of placental umbilical cord whole blood transfu-
sion in 62 patients as a rich source of fetal hemoglobin supply
in different indications of blood transfusion.  Clin Exp Obstet
Gynecol 2001, 28:47-52.
5. Bhattacharya N: Placental umbilical cord whole blood transfu-
sion: A safe and genuine blood substitute for patients of the
under-resourced world at emergency.  J Am Coll Surg 2005,
200:557-563.
6. Bhattacharya N: Placental umbilical cord blood transfusion in
transfusion-dependent beta thalassemic patients: a prelimi-
nary communication.  Clin Exp Obstet Gynecol 2005, 32:102-6.
7. Weiss G: Pathogenesis and treatment of anaemia of chronic
disease.  Blood Rev 2002, 16:87-96.
8. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK,
Ganz T: IL-6 mediates hypoferremia of inflammation by
inducing the synthesis of the iron regulatory hormone hepci-
din.  J Clin Invest 2004, 113:1271-1276.
9. Nicolas G, Bennoun M, Porteu A, Mativet S, Beaumont C, Grand-
champ B, Sirito M, Sawadogo M, Kahn A, Vaulont S: Severe iron
deficiency anaemia in transgenic mice expressing liver hep-
cidin.  Proc Natl Acad Sci USA 2002, 99:4596-4601.
10. Jelkmann W: Proinflammatory cytokines lowering erythropoi-
etin production.  J Interferon Cytokine Res 1998, 18:555-559.
11. Molsa M, Heikkinen T, Hakkola J, Hakala K, Wallerman O, Wadelius
M, Wadelius C, Laine K: Functional role of P-glycoprotein in the
human blood-placental barrier.  Clin Pharmacol Ther 2005,
78:118-22.
12. Tscherning-Casper C, Papadogiannakis N, Anvret M, Stolpe L, Lind-
gren S, Bohlin AB, Albert J, Fenyo EM: The trophoblastic epithe-
lial barrier is not infected in full-term placentae of human
immunodeficiency virus-seropositive mothers undergoing
antiretroviral therapy.  J Virol 1999, 73:9673-8.
13. McCracken S, Layton JE, Shorter SC, Starkey PM, Barlow DH, Mardon
HJ: Expression of granulocyte-colony stimulating factor and
its receptor is regulated during the development of the
human placenta.  J Endocrinol 1996, 149:249-258.
14. Chao NJ, Emerson SG, Weinberg KI: Stem Cell Transplantation
(Cord Blood Transplants).  Haematology 2004, 1:354-371.
15. Hassall O, Bedu-Addo G, Adarkwa M, Danso K, Bates I: Umbilical-
cord blood for transfusion in children with severe anaemia in
under-resourced countries.  Lancet 2003, 361:678-679.